Belite Bio (BLTE) EBIT (2022 - 2026)
Belite Bio's (BLTE) quarterly EBIT came in at -$32.7 million in Q1 2026, up 100.0% year-on-year from -$16.3 million in Q1 2025, and down 116308.45% quarter-over-quarter from -$28077.0 in Q4 2025.
Belite Bio (BLTE) EBIT (2022 - 2026) Analysis & Trends
Belite Bio's EBIT history runs 5 years deep, the most recent figure standing at -$32.7 million for Q1 2026.
- On a quarterly basis, EBIT rose 100.0% year-over-year to -$32.7 million in Q1 2026; TTM through Mar 2026 was -$17.6 billion, a 99.89% increase from a year earlier, with the FY2025 full-year figure at -$84.2 million, down 110.54% from the prior year.
- EBIT retreated to -$32.7 million in Q1 2026 per BLTE's latest filing, from -$28077.0 in the prior quarter.
- Across five years, EBIT topped out at -$9740.0 in Q3 2024 and bottomed at -$15517.0 billion in Q1 2025.
- The 5-year median for EBIT is -$1.3 billion (2022), against an average of -$973.3 billion.
- Across the five-year window, EBIT tumbled 186223.25% in 2025 and surged 100.0% in 2026, its largest moves.
- Year by year, EBIT stood at -$6.7 million in 2022, then declined by 3.48% to -$7.0 million in 2023, then jumped by 99.84% to -$11457.0 in 2024, then slumped by 145.06% to -$28077.0 in 2025, then plunged by 116308.45% to -$32.7 million in 2026.
- Per Business Quant, the three latest BLTE EBIT figures stand at -$32.7 million (Q1 2026), -$28077.0 (Q4 2025), and -$23018.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 268.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.68 Mn |
| Dec 31, 2025 | -28,077.00 |
| Sep 30, 2025 | -23,018.00 |
| Jun 30, 2025 | -17.60 Bn |
| Mar 31, 2025 | -15,517.00 Bn |
| Dec 31, 2024 | -11,457.00 |
| Sep 30, 2024 | -9,740.00 |
| Jun 30, 2024 | -10.47 Bn |
| Mar 31, 2024 | -8.33 Bn |
| Dec 31, 2023 | -6.96 Mn |
| Sep 30, 2023 | -10.96 Mn |
| Jun 30, 2023 | -6.87 Bn |
| Mar 31, 2023 | -6.88 Bn |
| Dec 31, 2022 | -6.72 Mn |
| Sep 30, 2022 | -2.54 Bn |
| Jun 30, 2022 | -2.51 Bn |